Moderna, Merck claim melanoma vaccine halves recurrence risk in Phase III trial

Moderna and Merck report melanoma vaccine cuts recurrence risk in trial of 1,137 patients

STAT • 24 Aug 08:35

A phase III study of the mRNA-based melanoma vaccine intismeran autogene showed a statistically significant reduction in the chance of disease recurrence or spread, according to results released by Moderna and Merck.

Moderna and Merck report positive Phase 3 results for melanoma mRNA vaccine

Gizmodo • 20 Aug 16:15

A Phase 3 trial showed that adding Moderna's personalized mRNA vaccine to Merck's Keytruda immunotherapy extended recurrence-free survival in high-risk melanoma patients.

Moderna shares dip after soaring on mRNA cancer vaccine trial success

Yahoo Finance • 20 Aug 09:10

Moderna's stock fell 12% in pre-market trading following a 177% jump on news that its mRNA melanoma vaccine met primary endpoints in a Phase 3 trial, prompting mixed reactions from analysts.

Moderna and Merck report mRNA vaccine improves recurrence-free survival in melanoma Phase 3 trial

Ars Technica • 19 Aug 16:53

A late-stage study of 1,137 melanoma patients showed that a personalized mRNA vaccine combined with Keytruda extended recurrence-free and distant metastasis-free survival, according to Moderna and Merck.

Moderna and Merck report experimental melanoma vaccine delays recurrence in late-stage trial

NBC News • 19 Aug 14:37

An mRNA-based personalized vaccine combined with Merck's Keytruda showed interim evidence of extending disease-free time for high-risk melanoma patients, according to a company release.